Form 4: Co-Diagnostics Director Durenard Boosts Stake

Co-Diagnostics, Inc. Director Eugene Durenard reported the acquisition of 57,499 shares of common stock through the vesting of restricted stock units.

Summary

• Eugene Durenard, a Director of Co-Diagnostics, Inc. (CODX), acquired 57,499 shares of common stock on November 23, 2025.
• The acquisition was a result of the vesting of previously awarded restricted stock units (RSUs) at a price of $0.00 per share.
• Following this transaction, Durenard directly beneficially owns 269,166 shares of common stock.
• The 57,499 shares represent a portion of multiple RSU awards granted under the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan.
• Specifically, these shares include installments from RSU awards granted on January 17, 2023 (40,000 units), June 12, 2023 (70,000 units), April 26, 2024 (110,000 units), and August 13, 2025 (125,000 units), all vesting in six equal installments every six months commencing on various dates.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. It's a routine, expected transaction (vesting of RSUs) which increases a director's direct ownership, aligning their interests with shareholders, but does not indicate new discretionary investment or significant operational news.

Positives

• The acquisition of shares by a director through RSU vesting demonstrates continued alignment of management's interests with shareholders.
• The transaction is part of a pre-established long-term incentive plan, indicating a structured approach to executive compensation and retention.

Future Outlook

NA

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically the vesting of restricted stock units for a director. It does not provide information directly related to broader industry trends or competitive landscape, but rather reflects internal compensation and ownership structures.

Stakeholder Impact

• Shareholders may view the increase in director ownership positively, as it further aligns management's interests with their own.
• Employees, particularly those with similar RSU compensation plans, may see this as a confirmation of the company's commitment to its long-term incentive programs.

Next Steps

• Future vesting events for the remaining restricted stock units held by the Reporting Person will occur every six months according to the established schedules for each award.

Key Dates

Recommendation

This filing reports a routine, scheduled vesting of restricted stock units for a director, not a discretionary purchase or sale. Such an event typically does not provide new fundamental information that would warrant a change in investment recommendation. It reflects standard compensation practices and continued insider ownership.

Keywords

Co-Diagnostics, CODX, Eugene Durenard, Director, Insider Transaction, Form 4, Restricted Stock Units, RSU Vesting, Stock Acquisition, Corporate Governance